Sort
261,768 grants matching “gene therapy”
A randomized, placebo-controlled, double-blind study to evaluate safety and efficacy of NDX-1017 treatment in Alzheimer's dementia patients
$2,926,978Hans Joerg Moebius · Athira Pharma, Inc. · R01 · FY2022 · AG
Characterizing WDR23 in Alzheimer's disease pathology
$2,924,025Sean P. Curran · University Of Southern California · RF1 · FY2019 · AG
Radiation Therapy Oncology Group
$2,923,989Walter John Curran · American College Of Radiology · U10 · FY2011 · CA
Optimization and Development of Non-Hallucinogenic 5-HT2A/2C Agonists as Opioid Use Disorder Therapeutics
$2,923,842Glenn Short III · Atai Therapeutics, Inc. · UG3 · FY2025 · DA
Overcoming mechanisms of therapeutic resistance in pancreatic ductal adenocarcinoma
$2,922,916Tony R. Hunter · Salk Institute For Biological Studies · P01 · FY2024 · CA
Advancing Apoptosis-Inducing Agents as Host-Directed Therapy for TB
$2,922,220Petros C Karakousis · Johns Hopkins University · R01 · FY2025 · AI
Center for Cell Circuits
$2,921,325Aviv Regev · Broad Institute, Inc. · P50 · FY2013 · HG
HYPERTHERMIA AND PERFUSION EFFECTS IN CANCER THERAPY
$2,921,194Duke University · P01 · FY2003 · CA
UCLA Center for AIDS Research (CFAR)
$2,920,591Jerome A. Zack · University Of California Los Angeles · P30 · FY2011 · AI
UCSD Alzheimer's Disease Research Center P50
$2,919,722Douglas R Galasko · University Of California, San Diego · P50 · FY2015 · AG
Informatics, Machine Learning & Biomedical Data Science
$2,918,456Calvin A Johnson · Center For Information Technology · ZIH · FY2019 · CT
Bioengineering of Bruch's Membrane for the treatment of Age-related Macular Degen
$2,918,000Magali Saint-Geniez · Schepens Eye Research Institute · DP2 · FY2009 · OD
Discovery and Development of Therapeutic Genes for CHF
$2,917,776H. Kirk Hammond · Veterans Medical Research Fdn/San Diego · P01 · FY2014 · HL
Genomics of Acute Myelogenous Leukemia
$2,917,422Timothy J Ley · Washington University · P01 · FY2017 · CA
Development of ITI-333, a μ-opioid Receptor Partial Agonist and 5HT2A and D1 Receptor Antagonist, for the Treatment of Opioid Use Disorders
$2,917,074Gretchen L Snyder · Intra-Cellular Therapies, Inc. · UG3 · FY2021 · DA
Studies of Populations Exposed to Environmental Sources of Radiation
$2,915,621Elizabeth Cahoon · Division Of Cancer Epidemiology And Genetics · ZIA · FY2024 · CA
Program Project in Models of Breast Cancer
$2,914,689Larry Norton · Sloan-Kettering Inst Can Research · P01 · FY2012 · CA
Single Cell Resolution Omics Analysis of T1D islets
$2,914,519Charles K Ansong · Battelle Pacific Northwest Laboratories · UC4 · FY2015 · DK
CHROME: Continuum of HIV Response through Observational Molecular Epidemiology
$2,911,005Joel Okrent Wertheim · University Of California, San Diego · R01 · FY2025 · AI
Genomic Approaches for Elucidating Novel Targets for Pain and Symptom Management
$2,909,970Ann Cashion · National Institute Of Nursing Research · ZIA · FY2012 · NR
The Alzheimer Disease Sequence Analysis Collaborative
$2,909,935Jonathan L. Haines · Case Western Reserve University · U01 · FY2020 · AG
Dissecting the mechanism of direct neural induction through genomic interrogation
$2,908,784Marius Wernig · Stanford University · RC4 · FY2010 · NS
Pharmacogenetics of Anticancer Agents Research Group
$2,908,227Mark J Ratain · University Of Chicago · U01 · FY2007 · GM
NEW METHODS FOR CANCER DETECTION
$2,908,154Weill Medical College Of Cornell Univ · P01 · FY2003 · CA
Drug Repurposing Screening for Rare and Neglected Diseases
$2,908,150Wei Zheng · National Center For Advancing Translational Sciences · ZIA · FY2019 · TR